**Supplemental Table 3.** The clinical characteristics related to AVS and tumors in patients from the discovery and validation cohorts.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Group** | **AVS** | **Tumor****side** | **Tumor****diameter****(mm)** |
| **lateralization side** | **LR** | **CR** | **SI** |
| **D1** | **UPA** | **L** | **9.3** | **0.7** | **L: 13.6 R: 19.1** | **L** | **15** |
| **D2** | **UPA** | **L** | **2.9** | **0.4** | **L: 20.8 R: 16.6** | **L** | **14** |
| **D3** | **UPA** | **L** | **4.8** | **1.1** | **L: 93.7 R: 52.0** | **L** | **10** |
| **D4** | **UPA** | **R** | **27.6** | **0.3** | **L: 33.2 R: 55.8** | **R** | **5** |
| **D5** | **UPA** | **L** | **10.8** | **0.5** | **L: 25.5 R: 32.8** | **L** | **15** |
| **D6** | **BHA** | **B** | **1.1** | **3.0** | **L: 42.0 R: 35.3** | **L** | **9** |
| **D7** | **BHA** | **B** | **1.7** | **1.7** | **L: 31.3 R: 28.2** |  |  |
| **D8** | **BHA** | **B** | **1.7** | **2.2** | **L: 26.3 R: 19.3** | **L** | **7** |
| **D9** | **BHA** | **B** | **1.4** | **2.8** | **L: 48.5 R: 56.3** |  |  |
| **D10** | **BHA** | **B** | **1.6** | **1.1** | **L: 93.6 R: 112.1** |  |  |
| **V1** | **UPA** | **L** | **7.8** | **0.9** | **L: 12.0 R: 25.6** | **L** | **10** |
| **V2** | **UPA** | **R** | **2.4** | **0.3** | **L: 19.1 R: 31.8** | **R** | **8** |
| **V3** | **UPA** | **L** | **4.1** | **1.9** | **L: 23.1 R: 43.0** | **L** | **9** |
| **V4** | **UPA** | **L** | **16.0** | **1.6** | **L: 37.5 R: 47.9** | **L** | **10** |
| **V5** | **UPA** | **R** | **6.5** | **1.4** | **L: 23.6 R: 31.5** | **R** | **5** |
| **V6** | **UPA** | **R** | **5.0** | **1.4** | **L: 28.3 R: 21.7** | **R** | **6** |
| **V7** | **UPA** | **L** | **5.2** | **0.8** | **L: 25.4 R: 55.5** | **L** | **5** |
| **V8** | **UPA** | **L** | **3.2** | **0.4** | **L: 7.7 R: 9.8** | **L** | **12** |
| **V9** | **UPA** | **L** | **5.4** | **0.6** | **L: 30.8 R: 11.6** | **L** | **18** |
| **V10** | **BHA** | **B** | **1.4** | **2.9** | **L: 17.6 R: 10.0** |  |  |
| **V11** | **BHA** | **B** | **1.4** | **2.8** | **L: 11.6 R: 10.1** |  |  |
| **V12** | **BHA** | **B** | **2.6** | **1.8** | **L: 67.6 R: 75.0** |  |  |
| **V13** | **BHA** | **B** | **1.6** | **2.9** | **L: 16.7 R: 12.5** | **R** | **22** |
| **V14** | **BHA** | **B** | **1.7** | **2.1** | **L: 16.5 R: 28.1** |  |  |
| **V15** | **BHA** | **B** | **1.1** | **2.3** | **L: 57.2 R: 42.9** | **R** | **17** |
| **V16** | **BHA** | **B** | **1.1** | **2.4** | **L: 44.9 R: 17.1** |  |  |
| **V17** | **BHA** | **B** | **2.8** | **2.6** | **L: 38.2 R: 20.0** | **L** | **11** |
| **V18** | **BHA** | **B** | **1.3** | **2.1** | **L: 36.5 R: 44.6** | **L** | **9** |

LR, lateralized ratio; CR, contralateral ratio; SI, selectivity index; L, left; R, right and B, bilateral. LR was calculated by dividing the aldosterone-to-cortisol ratio in the dominant adrenal vein by that in the non-dominant adrenal vein. CR was calculated by dividing the aldosterone-to-cortisol ratio in the non-dominant adrenal vein by that in the inferior vena cava. SI was defined as the ratio of the cortisol concentration in the adrenal vein to that in the inferior vena cava.